—  SHORT COURSE #22  —

Tumors In The Liver - Diagnostic Problems

Case 4 - Hepatocellular Carcinoma, Pseuglandular and Clear Cell Pattern

Linda D. Ferrell, M.D.
Wendy L. Frankel, M.D.


Clinical history:
62 year old man with history of colon cancer, presented with 2 month history of shoulder and epigastric pain. Abdominal MRI showed a 5 cm tumor in the lateral segment of the left hepatic lobe.


Case 4 - Figure 1 - Hepatocellular carcinoma, pseudoglandular pattern, medium power
Case 4 - Figure 2 - Hepatocellular carcinoma, clear cell variant, medium power
Case 4 - Figure 3 - Hepatocyte immunostain with granular cytoplasmic positivity, medium power



Case 4 - Figure 4 - pCEA immunostain with luminal and canalicular positivity, medium power
Case 4 - Figure 5 - Negative MOC31 immunostain, medium power


Pathologic findings:
The surface of the mass was irregular and the cut surface was tan-yellow and nodular. Microscopic sections showed hepatocytes arranged in a pseudoglandular pattern with some areas showing cells with clear cytoplasm.

Diagnosis: Hepatocellular Carcinoma, Pseuglandular And Clear Cell Pattern

References
  1. Borscheri N, Roessner A, Rocken C. Canalicular imunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinoma. Am J Surg Pathol 25:1297-1303, 2001.

  2. Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma. Am J Surg Pathol 26:978-988, 2002.

  3. Chu P, Wu E, Weiss L: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 13:962-972, 2000.

  4. Fan Z, van de Rijn M, Montgomery K, Rouse RV. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol 16:137-44, 2003.

  5. Fucich L, Cheles M, Thung S, et al: Primary versus metastatic hepatic carcinoma: An immunohistochemical study of 34 cases. Arch Pathol and Lab Med 118:927-930, 1994.

  6. Goodman Z, Ishak K, Langloss J, et al: Combined hepatocellular-cholangiocarcinoma: A histologic and immunohistochemical study. Cancer 55:124-135, 1985.

  7. Karkar S, Muir T, Murphy LM, Lloyd RV, Burgart LJ. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Am J Clin Pathol 119:361-6, 2003.

  8. Maeda T, Kajiyama K, Adachi E, et al: The expression of cytokeratins 7, 19, 20 in primary and metastatic carcinomas of the liver. Mod Pathol 9:901-909, 1996.

  9. Maitra A, Murkata LA, Albores-Saavedra J. Immunoreactivity for hepatcyte parafffin 1 antibody in adenocarcinoms of the gastrointestinal tract. Am J Clin Pathol 115:689-94, 2001.

  10. Minervini M, Demetris A, Lee R, et al: Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol 10:686-692, 1997.

  11. Morrison C, Marsh W, Frankel WL. A comparison of CD10 to pCEA, MOC-31 and hepatocyte for the distinction of malignant tumors in the liver, Mod Pathol 15:1279-1289, 2002.

  12. Murakata L, Ishak K, Nzeako U: Clear cell carcinoma of the liver: A comparative immunohistochemical study with renal clear cell carcinoma. Mod Pathol 13:874-881, 2000.

  13. Porcell AI, DeYoung BR, Proca DM, Frankel WL. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers. Mod Pathol 13:773-778, 2000.

  14. Renshaw A, Granter S: A comparison of A103 and inhibin reactivity in adrenal cortical tumors: distinction from hepatocellular carcinoma and renal tumors. Mod Pathol 11:1160-1164, 1998.

  15. Rullier A, Le Bail B, Fawaz R, et al: Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastases. Am J Surg Pathol 24:870-876, 2000.

  16. Wang J, Dhillon A, Sankey E, et al: Neuroendocrine differentiation in primary neoplasms of the liver. Journal of Pathology 163:61-67, 1991.

  17. Wang N, Zee S, Zarbo R, et al: Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Applied Immunohistochemistry 3:99-107, 1995.